Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:12/11/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the Company's on-going MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive MS and recommended that the trial continue.

This was the first of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study enrolling approximately 510 patients at more than 60 clinical sites who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

Recently the Company announced that more than 133 patients have been enrolled in its MAESTRO-03 trial. An interim safety and efficacy analysis will be performed on data from the first 133 patients enrolled when they have completed 24 months of the clinical trial.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Just the characterization of being a ... need does not guarantee immediate acceptance. In particular, ... many prior failures is often met with significant skepticism. ... an irony that is often an unappreciated aspect of ... Asymmetrex has found that building acceptance of ...
(Date:5/25/2015)... Phenome Networks, a software-as-a-service plant breeding ... beginning May 31st, of its next-generation Phenome One software. ... Phenome Networks’ lead in the plant breeding market, through ... breeding workflow based on years of experience with plant ... and more. The new version of Phenome One, Phenome ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Knowledgent ... white paper that explores the potential of big data ... white paper was developed to help life sciences and ... leverage data to gain critical business insights. , The ... amounts of data driven by patient profiling, compliance and ...
(Date:5/21/2015)... May 21, 2015 Specialty Pharmacy ... and been admitted to BPA Worldwide as a ... will track audience data for Specialty Pharmacy Times ... , “By becoming a member of BPA Worldwide, ... providing our clients with the most reliable, unequaled ...
Breaking Biology Technology:In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 2Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 3New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Specialty Pharmacy Times Joins BPA Worldwide 2
... 27, 2011 Cord Blood America, Inc . ( ... umbilical cord blood stem cell preservation company focused ... families nationwide and internationally, is pleased to announce it has ... Las Vegas laboratory for the National Children,s Leukemia Foundation (NCLF), ...
... 22, 2011 In recognition of the International Year of ... The Changing Role of Chemistry in Drug Discovery ... along with insights from industry experts, the new report forecasts ... the report suggests, a much more targeted, patient-specific approach will ...
... Mich., Dec. 22, 2011  Neogen Corporation (NASDAQ: NEOG ... of FY 2012, which ended Nov. 30, increased 2.2% from ... the quarter was $5,237,000, or $0.22 per share, compared to ... $0.26 per share. Year-to-date revenues for the first ...
Cached Biology Technology:Cord Blood America Announces Exclusive Agreement With National Children's Leukemia Foundation to Store Stem Cells 2Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era 2Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era 3Neogen Reports Second Quarter Results 2Neogen Reports Second Quarter Results 3Neogen Reports Second Quarter Results 4Neogen Reports Second Quarter Results 5Neogen Reports Second Quarter Results 6
(Date:5/7/2015)... 7, 2015 Fingerprint Cards ... and FPC1035, FPC,s smallest touch fingerprint sensors to ... considered for integration on the backside of the ... increased possibilities to integrate touch fingerprint sensors in ... improves possibilities for module manufacturers to customize the ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... California, San Diego and the University of Hawaii will ... as collaborative ties to Asian institutions to learn more ... off a much-feared pandemic in the region of the ... , "We will use modern high-throughput biology ...
... noise, like the crackle heard on AM radio when lightning ... devices. But within cells, a similar kind of biochemical "noise" ... according to a new study led by a UT Southwestern ... of pharmacology, said his research and that of his colleagues ...
... findings that help shape our understanding of how tool ... that chimpanzees, at least under some conditions, are capable ... prey. The work, reported by Jill Pruetz of Iowa ... Cambridge, will appear online in the journal Current Biology ...
Cached Biology News:Pacific Rim researchers to collaborate on distributed bioinformatics analysis of avian flu 2Pacific Rim researchers to collaborate on distributed bioinformatics analysis of avian flu 3Pacific Rim researchers to collaborate on distributed bioinformatics analysis of avian flu 4Pacific Rim researchers to collaborate on distributed bioinformatics analysis of avian flu 5Cells use 'noise' to make cell-fate decisions 2Cells use 'noise' to make cell-fate decisions 3Chimpanzees found to use tools to hunt mammalian prey 2
Request Info...
...
Request Info...
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: